Stevanović, Goran

Link to this page

Authority KeyName Variants
f5f4adda-5071-45a4-af0f-e8ab135abc0d
  • Stevanović, Goran (4)
Projects

Author's Bibliography

Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia

Janjušević, Ana; Ćirković, Ivana; Minić, Rajna; Stevanović, Goran; Soldatović, Ivan; Mihaljević, Biljana; Vidović, Ana; Marković-Denić, Ljiljana

(Multidisciplinary Digital Publishing Institute (MDPI), 2022)

TY  - JOUR
AU  - Janjušević, Ana
AU  - Ćirković, Ivana
AU  - Minić, Rajna
AU  - Stevanović, Goran
AU  - Soldatović, Ivan
AU  - Mihaljević, Biljana
AU  - Vidović, Ana
AU  - Marković-Denić, Ljiljana
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1260
UR  - http://intor.torlakinstitut.com/handle/123456789/625
AB  - The predictors of intestinal carriage of vancomycin-resistant Enterococcus spp. (VRE) among high-risk patients in the counties of the Southeast Europe Region are insufficiently investigated, yet they could be of key importance in infection control. The aim of the study was to identify risk factors associated with fecal VRE colonization among high-risk inpatients in university hospitals in Serbia. The study comprised 268 inpatients from three university hospitals. Data on patient demographics and clinical characteristics, length of hospital stay, therapy, and procedures were obtained from medical records. Chi-squared tests and univariate and multivariate logistic regressions were performed. Compared to the hemodialysis departments, stay in the geriatric departments, ICUs, and haemato-oncology departments increased the risk for VRE colonization 7.6, 5.4, and 5.5 times, respectively. Compared to inpatients who were hospitalized 48 h before stool sampling for VRE isolation, inpatients hospitalized 3–7, 8–15, and longer than 16 days before sampling had 5.0-, 4.7-, and 6.6-fold higher risk for VRE colonization, respectively. The use of cephalosporins and fluoroquinolones increased the risk for VRE colonization by 2.2 and 1.9 times, respectively. The age ≥ 65 years increased the risk for VRE colonization 2.3 times. In comparison to the University Clinical Centre of Serbia, the hospital stays at Zemun and Zvezdara University Medical Centres were identified as a protector factors. The obtained results could be valuable in predicting the fecal VRE colonization status at patient admission and consequent implementation of infection control measures targeting at-risk inpatients where VRE screening is not routinely performed.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Antibiotics
T1  - Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia
IS  - 9
SP  - 1228
VL  - 11
DO  - 10.3390/antibiotics11091228
ER  - 
@article{
author = "Janjušević, Ana and Ćirković, Ivana and Minić, Rajna and Stevanović, Goran and Soldatović, Ivan and Mihaljević, Biljana and Vidović, Ana and Marković-Denić, Ljiljana",
year = "2022",
abstract = "The predictors of intestinal carriage of vancomycin-resistant Enterococcus spp. (VRE) among high-risk patients in the counties of the Southeast Europe Region are insufficiently investigated, yet they could be of key importance in infection control. The aim of the study was to identify risk factors associated with fecal VRE colonization among high-risk inpatients in university hospitals in Serbia. The study comprised 268 inpatients from three university hospitals. Data on patient demographics and clinical characteristics, length of hospital stay, therapy, and procedures were obtained from medical records. Chi-squared tests and univariate and multivariate logistic regressions were performed. Compared to the hemodialysis departments, stay in the geriatric departments, ICUs, and haemato-oncology departments increased the risk for VRE colonization 7.6, 5.4, and 5.5 times, respectively. Compared to inpatients who were hospitalized 48 h before stool sampling for VRE isolation, inpatients hospitalized 3–7, 8–15, and longer than 16 days before sampling had 5.0-, 4.7-, and 6.6-fold higher risk for VRE colonization, respectively. The use of cephalosporins and fluoroquinolones increased the risk for VRE colonization by 2.2 and 1.9 times, respectively. The age ≥ 65 years increased the risk for VRE colonization 2.3 times. In comparison to the University Clinical Centre of Serbia, the hospital stays at Zemun and Zvezdara University Medical Centres were identified as a protector factors. The obtained results could be valuable in predicting the fecal VRE colonization status at patient admission and consequent implementation of infection control measures targeting at-risk inpatients where VRE screening is not routinely performed.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Antibiotics",
title = "Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia",
number = "9",
pages = "1228",
volume = "11",
doi = "10.3390/antibiotics11091228"
}
Janjušević, A., Ćirković, I., Minić, R., Stevanović, G., Soldatović, I., Mihaljević, B., Vidović, A.,& Marković-Denić, L.. (2022). Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia. in Antibiotics
Multidisciplinary Digital Publishing Institute (MDPI)., 11(9), 1228.
https://doi.org/10.3390/antibiotics11091228
Janjušević A, Ćirković I, Minić R, Stevanović G, Soldatović I, Mihaljević B, Vidović A, Marković-Denić L. Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia. in Antibiotics. 2022;11(9):1228.
doi:10.3390/antibiotics11091228 .
Janjušević, Ana, Ćirković, Ivana, Minić, Rajna, Stevanović, Goran, Soldatović, Ivan, Mihaljević, Biljana, Vidović, Ana, Marković-Denić, Ljiljana, "Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia" in Antibiotics, 11, no. 9 (2022):1228,
https://doi.org/10.3390/antibiotics11091228 . .

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults

Stevanović, Goran; Obradović, Aleksandar; Ristić, Snezana; Petrović, Dragan; Milenković, Branislava; Mitrović, Danilo; Vignjević Filipović, Svetlana; Ilić, Katarina; Stoiljković, Vera; Lavadinović, Lidija; Pelemis, Mijomir; Petrović, Svetlana; Vidmanić, Ana; Popović, Olga; Eremić, Natasa; Sparrow, Erin; Torelli, Guido; Socquet, Muriel; Holt, Renée; Ilieva-Borisova, Yordanka; Tang, Yuxiao; Scorza, Francesco Berlanda; Flores, Jorge; Rathi, Niraj

(SAGE Publications, 2020)

TY  - JOUR
AU  - Stevanović, Goran
AU  - Obradović, Aleksandar
AU  - Ristić, Snezana
AU  - Petrović, Dragan
AU  - Milenković, Branislava
AU  - Mitrović, Danilo
AU  - Vignjević Filipović, Svetlana
AU  - Ilić, Katarina
AU  - Stoiljković, Vera
AU  - Lavadinović, Lidija
AU  - Pelemis, Mijomir
AU  - Petrović, Svetlana
AU  - Vidmanić, Ana
AU  - Popović, Olga
AU  - Eremić, Natasa
AU  - Sparrow, Erin
AU  - Torelli, Guido
AU  - Socquet, Muriel
AU  - Holt, Renée
AU  - Ilieva-Borisova, Yordanka
AU  - Tang, Yuxiao
AU  - Scorza, Francesco Berlanda
AU  - Flores, Jorge
AU  - Rathi, Niraj
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/616
AB  - This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults between the ages of 18 and 65 years. This egg-based vaccine was manufactured by the Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia. A total of 480 participants were assigned randomly in a ratio of 2:1 to receive a single intramuscular dose (0.5 ml) of the vaccine (15 µg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Participants were monitored for safety, including solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). No SAEs related to vaccination were reported. Injection site pain (51.3%), injection site tenderness (40.4%), tiredness (17.0%), and headache (15.1%) were the most commonly reported solicited events in the vaccine group. Incidence of related unsolicited AEs was low (1.3%) among vaccinees. Hemagglutinin inhibition (HAI) titers were measured before and 21 days after vaccination in 151 participants. Overall, HAI seroconversion rates to H1 and H3 were observed in 90.1% and 76.2% of vaccinees, respectively. For B antigen, it was 51.5%, likely due to high pre-vaccination titers. Post-vaccination seroprotection rates were in the range of 78.2–95.0% for the three antigens. Post-vaccination geometric mean titers (GMT) were at least 3.8 times higher than baseline levels for all the three strains among vaccinees. Overall, the study showed that the vaccine was safe and well tolerated, and induced a robust immune response against all three vaccine strains., ClinicalTrials.gov identifier: NCT02935192, October 17, 2016
PB  - SAGE Publications
T2  - Therapeutic Advances in Vaccines and Immunotherapy
T1  - Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
VL  - 8
DO  - 10.1177/2515135520925336
ER  - 
@article{
author = "Stevanović, Goran and Obradović, Aleksandar and Ristić, Snezana and Petrović, Dragan and Milenković, Branislava and Mitrović, Danilo and Vignjević Filipović, Svetlana and Ilić, Katarina and Stoiljković, Vera and Lavadinović, Lidija and Pelemis, Mijomir and Petrović, Svetlana and Vidmanić, Ana and Popović, Olga and Eremić, Natasa and Sparrow, Erin and Torelli, Guido and Socquet, Muriel and Holt, Renée and Ilieva-Borisova, Yordanka and Tang, Yuxiao and Scorza, Francesco Berlanda and Flores, Jorge and Rathi, Niraj",
year = "2020",
abstract = "This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults between the ages of 18 and 65 years. This egg-based vaccine was manufactured by the Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia. A total of 480 participants were assigned randomly in a ratio of 2:1 to receive a single intramuscular dose (0.5 ml) of the vaccine (15 µg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Participants were monitored for safety, including solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). No SAEs related to vaccination were reported. Injection site pain (51.3%), injection site tenderness (40.4%), tiredness (17.0%), and headache (15.1%) were the most commonly reported solicited events in the vaccine group. Incidence of related unsolicited AEs was low (1.3%) among vaccinees. Hemagglutinin inhibition (HAI) titers were measured before and 21 days after vaccination in 151 participants. Overall, HAI seroconversion rates to H1 and H3 were observed in 90.1% and 76.2% of vaccinees, respectively. For B antigen, it was 51.5%, likely due to high pre-vaccination titers. Post-vaccination seroprotection rates were in the range of 78.2–95.0% for the three antigens. Post-vaccination geometric mean titers (GMT) were at least 3.8 times higher than baseline levels for all the three strains among vaccinees. Overall, the study showed that the vaccine was safe and well tolerated, and induced a robust immune response against all three vaccine strains., ClinicalTrials.gov identifier: NCT02935192, October 17, 2016",
publisher = "SAGE Publications",
journal = "Therapeutic Advances in Vaccines and Immunotherapy",
title = "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults",
volume = "8",
doi = "10.1177/2515135520925336"
}
Stevanović, G., Obradović, A., Ristić, S., Petrović, D., Milenković, B., Mitrović, D., Vignjević Filipović, S., Ilić, K., Stoiljković, V., Lavadinović, L., Pelemis, M., Petrović, S., Vidmanić, A., Popović, O., Eremić, N., Sparrow, E., Torelli, G., Socquet, M., Holt, R., Ilieva-Borisova, Y., Tang, Y., Scorza, F. B., Flores, J.,& Rathi, N.. (2020). Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults. in Therapeutic Advances in Vaccines and Immunotherapy
SAGE Publications., 8.
https://doi.org/10.1177/2515135520925336
Stevanović G, Obradović A, Ristić S, Petrović D, Milenković B, Mitrović D, Vignjević Filipović S, Ilić K, Stoiljković V, Lavadinović L, Pelemis M, Petrović S, Vidmanić A, Popović O, Eremić N, Sparrow E, Torelli G, Socquet M, Holt R, Ilieva-Borisova Y, Tang Y, Scorza FB, Flores J, Rathi N. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults. in Therapeutic Advances in Vaccines and Immunotherapy. 2020;8.
doi:10.1177/2515135520925336 .
Stevanović, Goran, Obradović, Aleksandar, Ristić, Snezana, Petrović, Dragan, Milenković, Branislava, Mitrović, Danilo, Vignjević Filipović, Svetlana, Ilić, Katarina, Stoiljković, Vera, Lavadinović, Lidija, Pelemis, Mijomir, Petrović, Svetlana, Vidmanić, Ana, Popović, Olga, Eremić, Natasa, Sparrow, Erin, Torelli, Guido, Socquet, Muriel, Holt, Renée, Ilieva-Borisova, Yordanka, Tang, Yuxiao, Scorza, Francesco Berlanda, Flores, Jorge, Rathi, Niraj, "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults" in Therapeutic Advances in Vaccines and Immunotherapy, 8 (2020),
https://doi.org/10.1177/2515135520925336 . .

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults

Stevanović, Goran; Lavadinović, Lidija; Filipović-Vignjević, Svetlana; Holt, Renee; Ilić, Katarina; Scorza, Francesco Berlanda; Sparrow, Erin; Stoiljković, Vera; Torelli, Guido; Madenwald, Tamra; Socquet, Muriel; Barac, Aleksandra; Ilieva-Borisova, Yordanka; Pelemiš, Mijomir; Flores, Jorge

(Taylor & Francis Inc, Philadelphia, 2018)

TY  - JOUR
AU  - Stevanović, Goran
AU  - Lavadinović, Lidija
AU  - Filipović-Vignjević, Svetlana
AU  - Holt, Renee
AU  - Ilić, Katarina
AU  - Scorza, Francesco Berlanda
AU  - Sparrow, Erin
AU  - Stoiljković, Vera
AU  - Torelli, Guido
AU  - Madenwald, Tamra
AU  - Socquet, Muriel
AU  - Barac, Aleksandra
AU  - Ilieva-Borisova, Yordanka
AU  - Pelemiš, Mijomir
AU  - Flores, Jorge
PY  - 2018
UR  - http://intor.torlakinstitut.com/handle/123456789/517
AB  - This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18-45years, were enrolled in the trial. On the day of immunization, volunteers were randomly assigned to receive either a single dose of the trivalent seasonal influenza vaccine (15g of hemagglutinin per strain) or placebo (phosphate-buffered saline). Subjects were monitored for adverse events through a clinical history and physical examination, and blood was taken for testing at screening and on day 8 to assess vaccine safety. Serum samples obtained before and 21days after immunization were tested for influenza antibody titers using hemagglutination-inhibition (HAI) and microneutralization (MN) tests. No serious adverse events were reported. Pain and tenderness at the injection site were the most commonly reported symptoms in both vaccine and placebo groups. Overall, serum HAI responses of fourfold or greater magnitude were observed to H1, H3, and B antigen in 80%, 75%, and 70% of subjects, respectively. Seroprotection rates as measured by HAI were also high (100%, 100% and 86.67%, respectively, for H1, H3 and B). Thus, Torlak's seasonal trivalent influenza vaccine was not associated with adverse events, was well-tolerated and immunogenic. It should be further evaluated in clinical trials to provide sufficient safety and immunogenicity data for licensing in Serbia.
PB  - Taylor & Francis Inc, Philadelphia
T2  - Human Vaccines & Immunotherapeutics
T1  - Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
EP  - 586
IS  - 3
SP  - 579
VL  - 14
DO  - 10.1080/21645515.2017.1415683
UR  - conv_427
ER  - 
@article{
author = "Stevanović, Goran and Lavadinović, Lidija and Filipović-Vignjević, Svetlana and Holt, Renee and Ilić, Katarina and Scorza, Francesco Berlanda and Sparrow, Erin and Stoiljković, Vera and Torelli, Guido and Madenwald, Tamra and Socquet, Muriel and Barac, Aleksandra and Ilieva-Borisova, Yordanka and Pelemiš, Mijomir and Flores, Jorge",
year = "2018",
abstract = "This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18-45years, were enrolled in the trial. On the day of immunization, volunteers were randomly assigned to receive either a single dose of the trivalent seasonal influenza vaccine (15g of hemagglutinin per strain) or placebo (phosphate-buffered saline). Subjects were monitored for adverse events through a clinical history and physical examination, and blood was taken for testing at screening and on day 8 to assess vaccine safety. Serum samples obtained before and 21days after immunization were tested for influenza antibody titers using hemagglutination-inhibition (HAI) and microneutralization (MN) tests. No serious adverse events were reported. Pain and tenderness at the injection site were the most commonly reported symptoms in both vaccine and placebo groups. Overall, serum HAI responses of fourfold or greater magnitude were observed to H1, H3, and B antigen in 80%, 75%, and 70% of subjects, respectively. Seroprotection rates as measured by HAI were also high (100%, 100% and 86.67%, respectively, for H1, H3 and B). Thus, Torlak's seasonal trivalent influenza vaccine was not associated with adverse events, was well-tolerated and immunogenic. It should be further evaluated in clinical trials to provide sufficient safety and immunogenicity data for licensing in Serbia.",
publisher = "Taylor & Francis Inc, Philadelphia",
journal = "Human Vaccines & Immunotherapeutics",
title = "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults",
pages = "586-579",
number = "3",
volume = "14",
doi = "10.1080/21645515.2017.1415683",
url = "conv_427"
}
Stevanović, G., Lavadinović, L., Filipović-Vignjević, S., Holt, R., Ilić, K., Scorza, F. B., Sparrow, E., Stoiljković, V., Torelli, G., Madenwald, T., Socquet, M., Barac, A., Ilieva-Borisova, Y., Pelemiš, M.,& Flores, J.. (2018). Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. in Human Vaccines & Immunotherapeutics
Taylor & Francis Inc, Philadelphia., 14(3), 579-586.
https://doi.org/10.1080/21645515.2017.1415683
conv_427
Stevanović G, Lavadinović L, Filipović-Vignjević S, Holt R, Ilić K, Scorza FB, Sparrow E, Stoiljković V, Torelli G, Madenwald T, Socquet M, Barac A, Ilieva-Borisova Y, Pelemiš M, Flores J. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. in Human Vaccines & Immunotherapeutics. 2018;14(3):579-586.
doi:10.1080/21645515.2017.1415683
conv_427 .
Stevanović, Goran, Lavadinović, Lidija, Filipović-Vignjević, Svetlana, Holt, Renee, Ilić, Katarina, Scorza, Francesco Berlanda, Sparrow, Erin, Stoiljković, Vera, Torelli, Guido, Madenwald, Tamra, Socquet, Muriel, Barac, Aleksandra, Ilieva-Borisova, Yordanka, Pelemiš, Mijomir, Flores, Jorge, "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults" in Human Vaccines & Immunotherapeutics, 14, no. 3 (2018):579-586,
https://doi.org/10.1080/21645515.2017.1415683 .,
conv_427 .
15
3
2
3

Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014

Dimitrijević, Dragana; Ilić, Dragan; Rakić-Adrović, Slavica; Šuljagić, Vesna; Pelemiš, Mijomir; Stevanović, Goran; Milinković, Milunka; Sipetić-Grujicić, Sandra

(Natl Inst Infectious Diseases, Tokyo, 2017)

TY  - JOUR
AU  - Dimitrijević, Dragana
AU  - Ilić, Dragan
AU  - Rakić-Adrović, Slavica
AU  - Šuljagić, Vesna
AU  - Pelemiš, Mijomir
AU  - Stevanović, Goran
AU  - Milinković, Milunka
AU  - Sipetić-Grujicić, Sandra
PY  - 2017
UR  - http://intor.torlakinstitut.com/handle/123456789/498
AB  - A retrospective analysis of the surveillance data on laboratory confirmed cases of influenza in 4 post pandemic seasons in Serbia was performed to evaluate predictors of hospitalization and admission to intensive care units (ICU). The specimens, including nasal and throat swabs were tested for influenza. Univariate and multivariate logistic regression analyses were perfoimed. Data of a total of 777 confirmed influenza cases were analyzed. Age  gt  65 years, the presence of any co-morbidity or the presence of  gt = 2 comorbidities, infection with influenza virus subtype A (H1) pdm09, and an interval greater than 3 days between symptom onset and the first physician visit, were independently associated with hospital admission. These variables, as well as infection with non-subtype influenza virus A, were predictors for ICU admission. Obesity and chronic neurological disease were independent predictors for ICU admission but not hospitalization. Overall, 41.7% of patients with influenza had at least one co-morbidity, but only 3% of all patients were vaccinated against influenza. Identification of high risk groups and education of these groups regarding their increased susceptibility to severe forms of influenza, and in particular regarding the importance of influenza vaccination, is essential.
PB  - Natl Inst Infectious Diseases, Tokyo
T2  - Japanese Journal of Infectious Diseases
T1  - Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014
EP  - 283
IS  - 3
SP  - 275
VL  - 70
DO  - 10.7883/yoken.JJID.2016.210
UR  - conv_412
ER  - 
@article{
author = "Dimitrijević, Dragana and Ilić, Dragan and Rakić-Adrović, Slavica and Šuljagić, Vesna and Pelemiš, Mijomir and Stevanović, Goran and Milinković, Milunka and Sipetić-Grujicić, Sandra",
year = "2017",
abstract = "A retrospective analysis of the surveillance data on laboratory confirmed cases of influenza in 4 post pandemic seasons in Serbia was performed to evaluate predictors of hospitalization and admission to intensive care units (ICU). The specimens, including nasal and throat swabs were tested for influenza. Univariate and multivariate logistic regression analyses were perfoimed. Data of a total of 777 confirmed influenza cases were analyzed. Age  gt  65 years, the presence of any co-morbidity or the presence of  gt = 2 comorbidities, infection with influenza virus subtype A (H1) pdm09, and an interval greater than 3 days between symptom onset and the first physician visit, were independently associated with hospital admission. These variables, as well as infection with non-subtype influenza virus A, were predictors for ICU admission. Obesity and chronic neurological disease were independent predictors for ICU admission but not hospitalization. Overall, 41.7% of patients with influenza had at least one co-morbidity, but only 3% of all patients were vaccinated against influenza. Identification of high risk groups and education of these groups regarding their increased susceptibility to severe forms of influenza, and in particular regarding the importance of influenza vaccination, is essential.",
publisher = "Natl Inst Infectious Diseases, Tokyo",
journal = "Japanese Journal of Infectious Diseases",
title = "Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014",
pages = "283-275",
number = "3",
volume = "70",
doi = "10.7883/yoken.JJID.2016.210",
url = "conv_412"
}
Dimitrijević, D., Ilić, D., Rakić-Adrović, S., Šuljagić, V., Pelemiš, M., Stevanović, G., Milinković, M.,& Sipetić-Grujicić, S.. (2017). Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014. in Japanese Journal of Infectious Diseases
Natl Inst Infectious Diseases, Tokyo., 70(3), 275-283.
https://doi.org/10.7883/yoken.JJID.2016.210
conv_412
Dimitrijević D, Ilić D, Rakić-Adrović S, Šuljagić V, Pelemiš M, Stevanović G, Milinković M, Sipetić-Grujicić S. Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014. in Japanese Journal of Infectious Diseases. 2017;70(3):275-283.
doi:10.7883/yoken.JJID.2016.210
conv_412 .
Dimitrijević, Dragana, Ilić, Dragan, Rakić-Adrović, Slavica, Šuljagić, Vesna, Pelemiš, Mijomir, Stevanović, Goran, Milinković, Milunka, Sipetić-Grujicić, Sandra, "Predictors of Hospitalization and Admission to Intensive Care Units of Influenza Patients in Serbia through Four Influenza Seasons from 2010/2011 to 2013/2014" in Japanese Journal of Infectious Diseases, 70, no. 3 (2017):275-283,
https://doi.org/10.7883/yoken.JJID.2016.210 .,
conv_412 .
9
8
9